Atrium Therapeutics, Inc. · NASDAQ:RNA
T. Rowe Price Associates Inc reported a 10.00% stake in Atrium Therapeutics, Inc. (Schedule 13G)
Event Mar 31, 2026 · Filed Apr 8, 2026
T. Rowe Price Associates Inc reported a 10.00% stake in Atrium Therapeutics, Inc., 1,553,210 shares, as a passive investor on Mar 31, 2026. Filed Apr 8, 2026 (Schedule 13G).
- Stake
- 10.00%
- Shares
- 1,553,210
- Intent
- Passive
- What changed
- Crossed above 5%
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| T. Rowe Price Associates, Inc. | 10.00% | 1,553,210 |
Source
Related
- Atrium Therapeutics, Inc.
- T. Rowe Price Associates Inc
- Atrium Therapeutics, Inc. shareholders
- Schedule 13G/A · T. Rowe Price Associates Inc · Aug 14, 2026
- Form 4 · Younis Husam · Sep 22, 2026
- Form 4 · Hughes Steven George · Sep 22, 2026
- Form 4 · Flanagan W. Michael · Sep 22, 2026
- Form 4 · Boyce Sarah · Sep 22, 2026
- Form 4 · Kenney Stephanie · Sep 22, 2026